The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Risk factors for anticoagulant-associated gastrointestinal hemorrhage: a systematic review and meta-analysis

  • Fuxin Ma (Department of Pharmacy, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University) ;
  • Shuyi Wu (Department of Pharmacy, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University) ;
  • Shiqi Li (Department of Pharmacy, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University) ;
  • Zhiwei Zeng (Department of Pharmacy, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University) ;
  • Jinhua Zhang (Department of Pharmacy, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University)
  • Received : 2023.03.01
  • Accepted : 2023.08.11
  • Published : 2024.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background/Aims: There may be many predictors of anticoagulation-related gastrointestinal bleeding (GIB), but until now, systematic reviews and assessments of the certainty of the evidence have not been published. We conducted a systematic review to identify all risk factors for anticoagulant-associated GIB to inform risk prediction in the management of anticoagulation-related GIB. Methods: A systematic review and meta-analysis were conducted to search PubMed, EMBASE, Web of Science, and Cochrane Library databases (from inception through January 21, 2022) using the following search terms: anticoagulants, heparin, warfarin, dabigatran, rivaroxaban, apixaban, DOACs, gastrointestinal hemorrhage, risk factors. According to inclusion and exclusion criteria, studies of risk factors for anticoagulation-related GIB were identified. Risk factors for anticoagulant-associated GIB were used as the outcome index of this review. Results: We included 34 studies in our analysis. For anticoagulant-associated GIB, moderate-certainty evidence showed a probable association with older age, kidney disease, concomitant use of aspirin, concomitant use of the antiplatelet agent, heart failure, myocardial infarction, hematochezia, renal failure, coronary artery disease, helicobacter pylori infection, social risk factors, alcohol use, smoking, anemia, history of sleep apnea, chronic obstructive pulmonary disease, international normalized ratio (INR), obesity et al. Some of these factors are not included in current GIB risk prediction models. such as anemia, co-administration of gemfibrozil, co-administration of verapamil or diltiazem, INR, heart failure, myocardial infarction, etc. Conclusions: The study found that anemia, co-administration of gemfibrozil, co-administration of verapamil or diltiazem, INR, heart failure, myocardial infarction et al. were associated with anticoagulation-related GIB, and these factors were not in the existing prediction models. This study informs risk prediction for anticoagulant-associated GIB, it also informs guidelines for GIB prevention and future research.

Keywords

References

  1. Hirsh J, Guyatt G, Albers GW, Harrington R, Schunemann HJ. Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):110S-112S. https://doi.org/10.1378/chest.08-0652
  2. Abraham NS, Noseworthy PA, Yao X, Sangaralingham LR, Shah ND. Gastrointestinal safety of direct oral anticoagulants: a large population-based study. Gastroenterology 2017;152:1014-1022.e1. https://doi.org/10.1053/j.gastro.2016.12.018
  3. Jingke W, Zhiyi L, Guiqing L, et al. [Current status and progress of oral combination antithrombotic drug therapy]. Int J Cardiovasc Dis 2017;44:132-135. Chinese.
  4. Choudari CP, Palmer KR. Acute gastrointestinal haemorrhage in patients treated with anticoagulant drugs. Gut 1995;36:483-484.
  5. Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005;143:241-250. https://doi.org/10.7326/0003-4819-143-4-200508160-00005
  6. Sorensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009;374:1967-1974. https://doi.org/10.1016/S0140-6736(09)61751-7
  7. van Leerdam ME, Vreeburg EM, Rauws EA, et al. Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. Am J Gastroenterol 2003;98:1494-1499. https://doi.org/10.1111/j.1572-0241.2003.07517.x
  8. Hearnshaw SA, Logan RF, Lowe D, Travis SP, Murphy MF, Palmer KR. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011;60:1327-1335. https://doi.org/10.1136/gut.2010.228437
  9. Rosenstock SJ, Moller MH, Larsson H, et al. Improving quality of care in peptic ulcer bleeding: nationwide cohort study of 13,498 consecutive patients in the Danish Clinical Register of Emergency Surgery. Am J Gastroenterol 2013;108:1449-1457. https://doi.org/10.1038/ajg.2013.162
  10. Darzi AJ, Karam SG, Charide R, et al. Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis. Blood 2020;135:1788-1810. https://doi.org/10.1182/blood.2019003603
  11. Riley RD, Moons KGM, Snell KIE, et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ 2019;364:k4597.
  12. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
  13. Tang SW, Zhang Y, Tao BL, Yang ZR, Sun F, Zhan SY. [Risk of bias assessment: (7) assessing bias in studies of prognostic factors]. Zhonghua Liu Xing Bing Xue Za Zhi 2018;39:1003-1008. Chinese.
  14. Hayden JA, van der Windt DA, Cartwright JL, Cote P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med 2013;158:280-286. https://doi.org/10.7326/0003-4819-158-4-201302190-00009
  15. Reeves BC, Deeks JJ, Higgins JPT, Wells GA. Including non-randomized studies. In: Higgins JPT, Thomas J, Chandler J, et al., eds. Cochrane Handbook for Systematic Reviews of Interventions. Cochrane, 2008:391.
  16. Iorio A, Spencer FA, Falavigna M, et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ 2015;350:h870.
  17. Grant RL. Converting an odds ratio to a range of plausible relative risks for better communication of research findings. BMJ 2014;348:f7450.
  18. Wang Z. Converting odds ratio to relative risk in cohort studies with partial data information. J Stat Softw 2013;55:1-11. https://doi.org/10.18637/jss.v055.i05
  19. Agudo-Fernandez S, Castano Milla C, Gonzalez Blanco A, Olmos Jerez JA, Calvo Morillas I, Sancho Del Val L. RHEDAR study: determination of the risk of gastrointestinal hemorrhage in treatment with dabigatran, acenocoumarol and rivaroxaban. J Gastroenterol Hepatol 2021;36:2794-2802. https://doi.org/10.1111/jgh.15547
  20. Fanning L, Wong ICK, Li X, et al. Gastrointestinal bleeding risk with rivaroxaban vs aspirin in atrial fibrillation: a multinational study. Pharmacoepidemiol Drug Saf 2020;29:1550-1561. https://doi.org/10.1002/pds.5130
  21. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015;131:157-164. https://doi.org/10.1161/CIRCULATIONAHA.114.012061
  22. Aisenberg J, Chatterjee-Murphy P, Friedman Flack K, et al. Gastrointestinal bleeding with edoxaban versus warfarin: results from the ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction). Circ Cardiovasc Qual Outcomes 2018;11:e003998.
  23. Chan EW, Lau WC, Leung WK, et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. Gastroenterology 2015;149:586-595.e3. https://doi.org/10.1053/j.gastro.2015.05.002
  24. Chen WC, Chen YH, Hsu PI, et al. Gastrointestinal hemorrhage in warfarin anticoagulated patients: incidence, risk factor, management, and outcome. Biomed Res Int 2014;2014:463767.
  25. Coates J, Bitton E, Hendje A, et al. Clinical outcomes of dabigatran use in patients with non-valvular atrial fibrillation and weight >120 kg. Thromb Res 2021;208:176-180. https://doi.org/10.1016/j.thromres.2021.11.007
  26. Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007;177:347-351. https://doi.org/10.1503/cmaj.070186
  27. Douros A, Renoux C, Yin H, Filion KB, Suissa S, Azoulay L. Concomitant use of direct oral anticoagulants with antiplatelet agents and the risk of major bleeding in patients with nonvalvular atrial fibrillation. Am J Med 2019;132:191-199.e12. https://doi.org/10.1016/j.amjmed.2018.10.008
  28. Ferroni E, Denas G, Gennaro N, Fedeli U, Pengo V. Gender related differences in gastrointestinal bleeding with oral anticoagulation in atrial fibrillation. J Cardiovasc Pharmacol Ther 2022;27:10742484211054609.
  29. Gandhi SK, Reiffel JA, Boiron R, Wieloch M. Risk of major bleeding in patients with atrial fibrillation taking dronedarone in combination with a direct acting oral anticoagulant (from a U.S. Claims Database). Am J Cardiol 2021;159:79-86. https://doi.org/10.1016/j.amjcard.2021.08.015
  30. Garcia DA, Fisher DA, Mulder H, et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J 2020;221:1-8. https://doi.org/10.1016/j.ahj.2019.10.013
  31. Holm J, Mannheimer B, Malmstrom RE, Eliasson E, Lindh JD. Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants-a Swedish, register-based cohort study in atrial fibrillation outpatients. Eur J Clin Pharmacol 2021;77:409-419. https://doi.org/10.1007/s00228-020-03015-7
  32. Holt A, Blanche P, Zareini B, et al. Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients on non-vitamin K oral anticoagulants. Heart 2022;108:626-632.
  33. Kato ET, Giugliano RP, Ruff CT, et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc 2016;5:e003432.
  34. Kalil RS, Kaboli PJ, Liu X, Vaughan-Sarrazin M. Association between renal function and bleeding risk for dabigatran after switching from warfarin. Am J Nephrol 2016;44:11-18. https://doi.org/10.1159/000446848
  35. Kolb JM, Flack KF, Chatterjee-Murphy P, et al. Locations and mucosal lesions responsible for major gastrointestinal bleeding in patients on warfarin or dabigatran. Dig Dis Sci 2018;63:1878-1889. https://doi.org/10.1007/s10620-018-5007-6
  36. Lauffenburger JC, Rhoney DH, Farley JF, Gehi AK, Fang G. Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy. Pharmacotherapy 2015;35:560-568. https://doi.org/10.1002/phar.1597
  37. Lee SR, Choi EK, Jung JH, et al. Body mass index and clinical outcomes in asian patients with atrial fibrillation receiving oral anticoagulation. Stroke 2021;52:521-530. https://doi.org/10.1161/STROKEAHA.120.030356
  38. Leonard CE, Brensinger CM, Bilker WB, et al. Gastrointestinal bleeding and intracranial hemorrhage in concomitant users of warfarin and antihyperlipidemics. Int J Cardiol 2017;228:761-770. https://doi.org/10.1016/j.ijcard.2016.11.245
  39. Maruyama K, Yamamoto T, Aoyagi H, et al. Difference between the upper and the lower gastrointestinal bleeding in patients taking nonvitamin K oral anticoagulants. Biomed Res Int 2018;2018:7123607.
  40. Murata N, Okumura Y, Nagashima K, et al.; SAKURA AF Registry Investigators. Gastrointestinal bleeding from oral anticoagulant therapy among Japanese patients with atrial fibrillation identified from the SAKURA atrial fibrillation registry. Circ J 2020;84:1475-1482. https://doi.org/10.1253/circj.CJ-20-0090
  41. Nantsupawat T, Soontrapa S, Nantsupawat N, et al. Risk factors and prevention of dabigatran-related gastrointestinal bleeding in patients with atrial fibrillation. J Arrhythm 2017;34:30-35. https://doi.org/10.1002/joa3.12015
  42. Nawarawong N, Pongprasobchai S, Tanwandee T. Acute gastrointestinal bleeding in anticoagulated patients: prevalence and predictors of significant endoscopic lesions and change of the management. J Med Assoc Thai 2018;101:135.
  43. Olsen AS, McGettigan P, Gerds TA, et al. Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study. Eur Heart J Cardiovasc Pharmacother 2020;6:292-300. https://doi.org/10.1093/ehjcvp/pvz069
  44. Pham P, Schmidt S, Lesko L, Lip GYH, Brown JD. Association of oral anticoagulants and verapamil or diltiazem with adverse bleeding events in patients with nonvalvular atrial fibrillation and normal kidney function. JAMA Netw Open 2020;3:e203593.
  45. Pourafkari L, Ghaffari S, Zamani N, et al. Upper gastrointestinal bleeding in the setting of excessive warfarin anticoagulation: risk factors, and clinical outcome. Cor et Vasa 2017;59:e128-e133. https://doi.org/10.1016/j.crvasa.2016.03.006
  46. Schauer DP, Moomaw CJ, Wess M, Webb T, Eckman MH. Psychosocial risk factors for adverse outcomes in patients with nonvalvular atrial fibrillation receiving warfarin. J Gen Intern Med 2005;20:1114-1119. https://doi.org/10.1111/j.1525-1497.2005.0242.x
  47. Sherid M, Sifuentes H, Sulaiman S, et al. Gastrointestinal bleeding with dabigatran, a comparative study with warfarin: a multicenter experience. Korean J Gastroenterol 2015;65:205-214. https://doi.org/10.4166/kjg.2015.65.4.205
  48. Sherid M, Sifuentes H, Sulaiman S, et al. Risk of gastrointestinal bleeding with dabigatran: a head-to-head comparative study with rivaroxaban. Digestion 2014;90:137-146. https://doi.org/10.1159/000365967
  49. Sherid M, Sulaiman S, Samo S, et al. Risk of gastrointestinal bleeding with rivaroxaban: a comparative study with warfarin. Gastroenterol Res Pract 2016;2016:9589036.
  50. Sherwood MW, Nessel CC, Hellkamp AS, et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF trial. J Am Coll Cardiol 2015;66:2271-2281. https://doi.org/10.1016/j.jacc.2015.09.024
  51. Youn SH, Lim H, Ju Y, et al. Effect of gastroprotective agents on upper gastrointestinal bleeding in patients receiving direct oral anticoagulants. Scand J Gastroenterol 2018;53:1490-1495. https://doi.org/10.1080/00365521.2018.1541478
  52. Shimomura A, Nagata N, Shimbo T, et al. New predictive model for acute gastrointestinal bleeding in patients taking oral anticoagulants: a cohort study. J Gastroenterol Hepatol 2018;33:164-171. https://doi.org/10.1111/jgh.13830
  53. Lopez-Jimenez L, Montero M, Gonzalez-Fajardo JA, et al.; RIETE Investigators. Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). Haematologica 2006;91:1046-1051.
  54. Cuschieri JR, Drawz P, Falck-Ytter Y, Wong RC. Risk factors for acute gastrointestinal bleeding following myocardial infarction in veteran patients who are prescribed clopidogrel. J Dig Dis 2014;15:195-201. https://doi.org/10.1111/1751-2980.12123
  55. de Groot NL, Hagenaars MP, Smeets HM, Steyerberg EW, Siersema PD, van Oijen MG. Primary non-variceal upper gastrointestinal bleeding in NSAID and low-dose aspirin users: development and validation of risk scores for either medication in two large Dutch cohorts. J Gastroenterol 2014;49:245-253. https://doi.org/10.1007/s00535-013-0817-y
  56. Xu W, Lv M, Wu S, et al. Severe bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention and treatment in patients with atrial fibrillation: a systematic review and network meta-analysis. Cardiovasc Drugs Ther 2023;37:363-377. https://doi.org/10.1007/s10557-021-07232-9
  57. Ray WA, Chung CP, Murray KT, et al. Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding. Gastroenterology 2016;151:1105-1112.e10. https://doi.org/10.1053/j.gastro.2016.08.054